UNSPSC 51294000: Antidepressant morpholines

Antidepressant drugs made from tetrahydro-1,4-oxazines, six-membered heterocycles with amine and ether functional groups.

UNSPSC 51294000 Antidepressant morpholines is a Class code that shows significant mismatch between its nominal scope and recent state and local procurement activity. The three recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which align with antidepressant morpholine medications. Antidepressants in this chemical class are typically prescribed at individual patient levels rather than procured in bulk by state and local health or benefit programs; the code appears to be a misclassification artifact in the sourced opportunities rather than a reflection of genuine state and local demand for this specific pharmaceutical category. The issuing bodies represent a mix of county health departments, state health and human services commissions, and state cooperative purchasing alliances, but their actual procurement needs fall outside the code's nominal scope.

The three opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems through its community health program, with quarterly deliveries required and potential FEMA funding. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs serving the state's pharmacy benefit systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with contracts effective July 1, 2026. Given the disconnect between the code's stated focus and the work actually being solicited, this code shows little relevant recent activity for business development purposes in the antidepressant morpholine space.